SCHEMBL5216979

SCHEMBL5216979

Cc1cc(C)cc(-n2cc(-c3ccc4ccccc4n3)cn2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.44
RAB9A P51151 9/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 7/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
MAPT P10636 6/20 0.43
ALDH1A1 P00352 6/20 0.43
TP53 P04637 3/20 0.43
HPGD P15428 3/20 0.43
CYP3A4 P08684 2/20 0.43
GMNN O75496 1/20 0.43
PKM P14618 1/20 0.43
THPO P40225 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
HSD17B10 Q99714 1/20 0.43
XBP1 P17861 1/20 0.42
KLF5 Q13887 1/20 0.42
AR P10275 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5218479 0.84 NPC1 (0.50) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL5215869 0.82 AHR (0.48) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL5220745 0.80 NPC1 (0.43) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL5256274 0.79 GRM5 (0.40) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL5215816 0.79 DYRK1B (0.41) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL29638020 0.77 NPC1 (0.59) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL10079213 0.77 NPC1 (0.59) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL5217060 0.77 NPC1 (0.41) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL5218147 0.76 NPC1 (0.42) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL17272764 0.76 PDE10A (0.53) NPC1RAB9AMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C NPC1 4205/4885RAB9A 1352/4885MEN1 4569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.